News Related to Wells Fargo

Related coverage linked through entity extraction aliases.

FDA Rejects uniQure's AMT-130 Data as Insufficient for Approval, Demands Sham-Controlled Trial

Mar 03, 2026

The FDA informed uniQure that Phase 1/2 study data for AMT-130 in Huntington's disease is insufficient to support a biologics license application, recommending a prospective, randomized, double-blind, sham surgery-controlled study instead.

Analysts Raise Price Targets on Praxis Precision Medicines Following Clinical Progress

Feb 24, 2026

Multiple analysts have raised price targets on Praxis Precision Medicines, with Wolfe Research initiating coverage at $500 and Guggenheim increasing its target to $800, citing strong market potential for ulixacaltamide in essential tremor.